{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T11:18:14Z","timestamp":1788952694902,"version":"build-2803163510"},"reference-count":73,"publisher":"Radcliffe Medical Media Ltd","license":[{"start":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T00:00:00Z","timestamp":1788825600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/legalcode"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Card Fail Rev"],"abstract":"<jats:p>The prevalence of obesity among the general population has resulted in significant overlap and complex interactions with heart failure. This review aims to describe recent changes to the definition of obesity and explore direct and indirect mechanistic links between obesity and heart failure. Diagnostic challenges presented by obesity regarding echocardiography and B-type natriuretic peptide are also explored. Treatment options and the evidence base for addressing obesity in heart failure are examined across both heart failure with preserved ejection fraction and heart failure with reduced ejection fraction. Finally, the safety profile of new incretin-based therapies is examined.<\/jats:p>","DOI":"10.15420\/cfr.2026.05","type":"journal-article","created":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T14:19:33Z","timestamp":1788704373000},"source":"Crossref","is-referenced-by-count":0,"title":["Obesity in Heart Failure: Mechanistic, Diagnostic and Therapeutic Considerations"],"prefix":"10.15420","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0939-5470","authenticated-orcid":false,"given":"Faraz","family":"Pathan","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/046fa4y88","id-type":"ROR","asserted-by":"publisher"}],"name":"The Heart Research Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1922-3058","authenticated-orcid":false,"given":"Kathryn","family":"Williams","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/0384j8v12","id-type":"ROR","asserted-by":"publisher"}],"name":"The University of Sydney"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"6096","published-online":{"date-parts":[[2026,9,8]]},"reference":[{"key":"ref0","unstructured":"GBD 2021 Adult BMI Collaborators. Global, regional, and national prevalence of adult overweight and obesity, 1990\u20132021, with forecasts to 2050: a forecasting study for the Global Burden of Disease Study 2021. Lancet 2025;405:813\u201338. https:\/\/doi.org\/10.1016\/S0140-6736(25)00355-1; PMID: 40049186."},{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Kenchaiah S, Evans JC, Levy D, et al. Obesity and the risk of heart failure. N Engl J Med 2002;347:305\u201313. https:\/\/doi.org\/10.1056\/NEJMoa020245; PMID: 12151467. DOI: 10.1056\/NEJMoa020245","DOI":"10.1056\/NEJMoa020245"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Khan MS, Shahid I, Bennis A, et al. Global epidemiology of heart failure. Nat Rev Cardiol 2024;21:717\u201334. https:\/\/doi.org\/10.1038\/s41569-024-01046-6; PMID: 38926611. DOI: 10.1038\/s41569-024-01046-6","DOI":"10.1038\/s41569-024-01046-6"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Peikert A, Vaduganathan M, Claggett BL, et al. Near-universal prevalence of central adiposity in heart failure with preserved ejection fraction: the PARAGON-HF trial. Eur Heart J 2025;46:2372\u201390. https:\/\/doi.org\/10.1093\/eurheartj\/ehaf057; PMID: 39873282. DOI: 10.1093\/eurheartj\/ehaf057","DOI":"10.1093\/eurheartj\/ehaf057"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Kittleson MM, Benjamin EJ, Blumer V, et al. 2025 ACC scientific statement on the management of obesity in adults with heart failure: a report of the American College of Cardiology. J Am Coll Cardiol 2025;86:1953\u201375. https:\/\/doi.org\/10.1016\/j.jacc.2025.05.008; PMID: 40512113. DOI: 10.1016\/j.jacc.2025.05.008","DOI":"10.1016\/j.jacc.2025.05.008"},{"key":"ref5","unstructured":"Rubino F, Cummings DE, Eckel RH, et al. Definition and diagnostic criteria of clinical obesity. Lancet Diabetes Endocrinol 2025;13:221\u201362. https:\/\/doi.org\/10.1016\/S2213-8587(24)00316-4; PMID: 39824205."},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Huynh K, Ayers C, Butler J, et al. Association between thigh muscle fat infiltration and incident heart failure: the Health ABC study. JACC Heart Fail 2022;10:485\u201393. https:\/\/doi.org\/10.1016\/j.jchf.2022.04.012; PMID: 35772859. DOI: 10.1016\/j.jchf.2022.04.012","DOI":"10.1016\/j.jchf.2022.04.012"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Packer M. Do obesity and visceral adiposity promote heart failure with reduced ejection fraction? Eur Heart J 2026;47:12\u201321. https:\/\/doi.org\/10.1093\/eurheartj\/ehaf645; PMID: 40891153. DOI: 10.1093\/eurheartj\/ehaf645","DOI":"10.1093\/eurheartj\/ehaf645"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Arakelyan M, Golukhova EZ, Gromova OI, Bulaeva NI. Epicardial adipose tissue and nonvalvular atrial fibrillation. Eur Heart J 2021;42(Suppl 1):ehab724.0283. https:\/\/doi.org\/10.1093\/eurheartj\/ehab724.0283. DOI: 10.1093\/eurheartj\/ehab724.0283","DOI":"10.1093\/eurheartj\/ehab724.0283"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Filtz A, Lorenzatti D, Scotti A, et al. Relationship between epicardial adipose tissue and coronary atherosclerosis by CCTA in young adults (18\u201345). Am J Prev Cardiol 2024;19:100711. https:\/\/doi.org\/10.1016\/j.ajpc.2024.100711; PMID: 39157644. DOI: 10.1016\/j.ajpc.2024.100711","DOI":"10.1016\/j.ajpc.2024.100711"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Meems LMG, van Veldhuisen DJ, Sattar N, Lee MMY. Heart failure and obesity: novel insights leading to new treatment paradigms. Nat Rev Cardiol 2025;23:87\u201399. https:\/\/doi.org\/10.1038\/s41569-025-01190-7; PMID: 40721643. DOI: 10.1038\/s41569-025-01190-7","DOI":"10.1038\/s41569-025-01190-7"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Battineni G, Sagaro GG, Chintalapudi N, et al. Impact of obesity-induced inflammation on cardiovascular diseases (CVD). Int J Mol Sci 2021;22:4798. https:\/\/doi.org\/10.3390\/ijms22094798; PMID: 33946540. DOI: 10.3390\/ijms22094798","DOI":"10.3390\/ijms22094798"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Packer M. The adipokine hypothesis of heart failure with a preserved ejection fraction: a novel framework to explain pathogenesis and guide treatment. J Am Coll Cardiol 2025;86:1269\u2013373. https:\/\/doi.org\/10.1016\/j.jacc.2025.06.055; PMID: 40886173. DOI: 10.1016\/j.jacc.2025.06.055","DOI":"10.1016\/j.jacc.2025.06.055"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Rayner JJ, Abdesselam I, Pan J, et al. Obesity and heart failure: exploring the cardiometabolic axis. Cardiovasc Res 2025;121:1173\u201386. https:\/\/doi.org\/10.1093\/cvr\/cvaf090; PMID: 40458047. DOI: 10.1093\/cvr\/cvaf090","DOI":"10.1093\/cvr\/cvaf090"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Uphues I, Kolter T, Goud B, Eckel J. Failure of insulin-regulated recruitment of the glucose transporter GLUT4 in cardiac muscle of obese Zucker rats is associated with alterations of small-molecular-mass GTP-binding proteins. Biochem J 1995;311:161\u20136. https:\/\/doi.org\/10.1042\/bj3110161; PMID: 7575448. DOI: 10.1042\/bj3110161","DOI":"10.1042\/bj3110161"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"Coort SLM, Hasselbaink DM, Koonen DPY, et al. Enhanced sarcolemmal FAT\/CD36 content and triacylglycerol storage in cardiac myocytes from obese Zucker rats. Diabetes 2004;53:1655\u201363. https:\/\/doi.org\/10.2337\/diabetes.53.7.1655; PMID: 15220187. DOI: 10.2337\/diabetes.53.7.1655","DOI":"10.2337\/diabetes.53.7.1655"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"Unger RH. Lipotoxic diseases. Annu Rev Med 2002;53:319\u201336. https:\/\/doi.org\/10.1146\/annurev.med.53.082901.104057; PMID: 11818477. DOI: 10.1146\/annurev.med.53.082901.104057","DOI":"10.1146\/annurev.med.53.082901.104057"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"Cavalera M, Wang J, Frangogiannis NG. Obesity, metabolic dysfunction, and cardiac fibrosis: pathophysiological pathways, molecular mechanisms, and therapeutic opportunities. Transl Res 2014;164:323\u201335. https:\/\/doi.org\/10.1016\/j.trsl.2014.05.001; PMID: 24880146. DOI: 10.1016\/j.trsl.2014.05.001","DOI":"10.1016\/j.trsl.2014.05.001"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"Hall JE, do Carmo JM, da Silva AA, et al. Obesity, kidney dysfunction and hypertension: mechanistic links. Nat Rev Nephrol 2019;15:367\u201385. https:\/\/doi.org\/10.1038\/s41581-019-0145-4; PMID: 31015582. DOI: 10.1038\/s41581-019-0145-4","DOI":"10.1038\/s41581-019-0145-4"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"Reddy YNV, Melenovsky V, Redfield MM, et al. High-output heart failure: a 15-year experience. J Am Coll Cardiol 2016;68:473\u201382. https:\/\/doi.org\/10.1016\/j.jacc.2016.05.043; PMID: 27470455. DOI: 10.1016\/j.jacc.2016.05.043","DOI":"10.1016\/j.jacc.2016.05.043"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"Zhao H, Huang R, Jiang M, et al. Myocardial tissue-level characteristics of adults with metabolically healthy obesity. JACC Cardiovasc Imaging 2023;16:889\u2013901. https:\/\/doi.org\/10.1016\/j.jcmg.2023.01.022; PMID: 37052557. DOI: 10.1016\/j.jcmg.2023.01.022","DOI":"10.1016\/j.jcmg.2023.01.022"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"Pandey A, LaMonte M, Klein L, et al. Relationship between physical activity, body mass index, and risk of heart failure. J Am Coll Cardiol 2017;69:1129\u201342. https:\/\/doi.org\/10.1016\/j.jacc.2016.11.081; PMID: 28254175. DOI: 10.1016\/j.jacc.2016.11.081","DOI":"10.1016\/j.jacc.2016.11.081"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"Obokata M, Reddy YNV, Pislaru SV, et al. Evidence supporting the existence of a distinct obese phenotype of heart failure with preserved ejection fraction. Circulation 2017;136:6\u201319. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.116.026807; PMID: 28381470. DOI: 10.1161\/CIRCULATIONAHA.116.026807","DOI":"10.1161\/CIRCULATIONAHA.116.026807"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"Antonopoulos AS, Panagiotopoulos I, Terentes-Printzios D, et al. Relationship between obesity and hypertrophic or dilated cardiomyopathy: the role of sex. Clin Obes 2024;14:e12692. https:\/\/doi.org\/10.1111\/cob.12692; PMID: 38992899. DOI: 10.1111\/cob.12692","DOI":"10.1111\/cob.12692"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"Peng L, Zeng T, Quan E, et al. Obesity phenotypes causally affect cardiac MRI structure and induced non-ischaemic cardiomyopathy. Card Fail Rev 2025;11:e10. https:\/\/doi.org\/10.15420\/cfr.2024.26; PMID: 40395981. DOI: 10.15420\/cfr.2024.26","DOI":"10.15420\/cfr.2024.26"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"Hobbach AJ, Feld J, Linke WA, et al. BMI-stratified exploration of the \u2018obesity paradox\u2019: heart failure perspectives from a large German insurance database. J Clin Med 2024;13:2086. https:\/\/doi.org\/10.3390\/jcm13072086; PMID: 38610851. DOI: 10.3390\/jcm13072086","DOI":"10.3390\/jcm13072086"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"Wang X, Liu W, Li H, et al. Exploring the role of obesity in dilated cardiomyopathy based on bio-informatics analysis. J Cardiovasc Dev Dis 2022;9:462. https:\/\/doi.org\/10.3390\/jcdd9120462; PMID: 36547458. DOI: 10.3390\/jcdd9120462","DOI":"10.3390\/jcdd9120462"},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"Shah NM, Kaltsakas G. Respiratory complications of obesity: from early changes to respiratory failure. Breathe (Sheff) 2023;19:220263. https:\/\/doi.org\/10.1183\/20734735.0263-2022; PMID: 37378063. DOI: 10.1183\/20734735.0263-2022","DOI":"10.1183\/20734735.0263-2022"},{"key":"ref28","doi-asserted-by":"crossref","unstructured":"Reddy YNV, Carter RE, Obokata M, et al. A simple, evidence-based approach to help guide diagnosis of heart failure with preserved ejection fraction. Circulation 2018;138:861\u201370. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.118.034646; PMID: 29792299. DOI: 10.1161\/CIRCULATIONAHA.118.034646","DOI":"10.1161\/CIRCULATIONAHA.118.034646"},{"key":"ref29","doi-asserted-by":"crossref","unstructured":"Kosyakovsky LB, Liu EE, Wang JK, et al. Uncovering unrecognized heart failure with preserved ejection fraction among individuals with obesity and dyspnea. Circ Heart Fail 2024;17:e011366. https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.123.011366; PMID: 38742409. DOI: 10.1161\/CIRCHEARTFAILURE.123.011366","DOI":"10.1161\/CIRCHEARTFAILURE.123.011366"},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"Singh M, Sethi A, Mishra AK, et al. Echocardiographic imaging challenges in obesity: guideline recommendations and limitations of adjusting to body size. J Am Heart Assoc 2020;9:e014609. https:\/\/doi.org\/10.1161\/JAHA.119.014609; PMID: 31914879. DOI: 10.1161\/JAHA.119.014609","DOI":"10.1161\/JAHA.119.014609"},{"key":"ref31","unstructured":"Vergaro G, Gentile F, Meems LMG, et al. NT-proBNP for risk prediction in heart failure: identification of optimal cutoffs across body mass index categories. JACC Heart Fail 2021;9:653\u201363. https:\/\/doi.org\/10.1016\/j.jchf.2021.05.014; PMID: 34246607."},{"key":"ref32","doi-asserted-by":"crossref","unstructured":"Bianchettin RG, Lavie CJ, Lopez-Jimenez F. Challenges in cardiovascular evaluation and management of obese patients: JACC state-of-the-art review. J Am Coll Cardiol 2023;81:490\u2013504. https:\/\/doi.org\/10.1016\/j.jacc.2022.11.031; PMID: 36725178. DOI: 10.1016\/j.jacc.2022.11.031","DOI":"10.1016\/j.jacc.2022.11.031"},{"key":"ref33","doi-asserted-by":"crossref","unstructured":"Ellenberger K, Jeyaprakash P, Sivapathan S, et al. The effect of obesity on echocardiographic image quality. Heart Lung Circ 2022;31:207\u201315. https:\/\/doi.org\/10.1016\/j.hlc.2021.06.525; PMID: 34373191. DOI: 10.1016\/j.hlc.2021.06.525","DOI":"10.1016\/j.hlc.2021.06.525"},{"key":"ref34","doi-asserted-by":"crossref","unstructured":"Goyal A, Crabtree CD, Lee BC, et al. The impact of severe obesity on image quality and ventricular function assessment in echocardiography and cardiac MRI. Int J Cardiovasc Imaging 2024;40:1081\u201394. https:\/\/doi.org\/10.1007\/s10554-024-03078-y; PMID: 38625629. DOI: 10.1007\/s10554-024-03078-y","DOI":"10.1007\/s10554-024-03078-y"},{"key":"ref35","doi-asserted-by":"crossref","unstructured":"M\u00f8ller JE, Pellikka PA, Hillis GS, Oh JK. Prognostic importance of diastolic function and filling pressure in patients with acute myocardial infarction. Circulation 2006;114:438\u201344. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.105.601005; PMID: 16880341. DOI: 10.1161\/CIRCULATIONAHA.105.601005","DOI":"10.1161\/CIRCULATIONAHA.105.601005"},{"key":"ref36","doi-asserted-by":"crossref","unstructured":"Nagueh SF, Sanborn DY, Oh JK, et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography and for heart failure with preserved ejection fraction diagnosis: an update from the American Society of Echocardiography. J Am Soc Echocardiogr 2025;38:537\u201369. https:\/\/doi.org\/10.1016\/j.echo.2025.03.011; PMID: 40617625. DOI: 10.1016\/j.echo.2025.03.011","DOI":"10.1016\/j.echo.2025.03.011"},{"key":"ref37","doi-asserted-by":"crossref","unstructured":"Jeyaprakash P, Moussad A, Pathan S, et al. A systematic review of scaling left atrial size: are alternative indexation methods required for an increasingly obese population? J Am Soc Echocardiogr 2021;34:1067\u201376.e3. https:\/\/doi.org\/10.1016\/j.echo.2021.05.009; PMID: 34023453. DOI: 10.1016\/j.echo.2021.05.009","DOI":"10.1016\/j.echo.2021.05.009"},{"key":"ref38","doi-asserted-by":"crossref","unstructured":"Fung ASY, Soundappan D, Loewenstein DE, et al. Prognostic association supports indexing size measures in echocardiography by body surface area. Sci Rep 2023;13:19390. https:\/\/doi.org\/10.1038\/s41598-023-46183-z; PMID: 37938592. DOI: 10.1038\/s41598-023-46183-z","DOI":"10.1038\/s41598-023-46183-z"},{"key":"ref39","doi-asserted-by":"crossref","unstructured":"Obokata M, Reddy YNV, Melenovsky V, et al. Uncoupling between intravascular and distending pressures leads to underestimation of circulatory congestion in obesity. Eur J Heart Fail 2022;24:353\u201361. https:\/\/doi.org\/10.1002\/ejhf.2377; PMID: 34755429. DOI: 10.1002\/ejhf.2377","DOI":"10.1002\/ejhf.2377"},{"key":"ref40","doi-asserted-by":"crossref","unstructured":"Vaishnav J, Chasler JE, Lee YJ, et al. Highest obesity category associated with largest decrease in N-terminal pro-B-type natriuretic peptide in patients hospitalized with heart failure with preserved ejection fraction. J Am Heart Assoc 2020;9:e015738. https:\/\/doi.org\/10.1161\/JAHA.119.015738; PMID: 32750299. DOI: 10.1161\/JAHA.119.015738","DOI":"10.1161\/JAHA.119.015738"},{"key":"ref41","doi-asserted-by":"crossref","unstructured":"Buckley LF, Canada JM, Del Buono MG, et al. Low NT-proBNP levels in overweight and obese patients do not rule out a diagnosis of heart failure with preserved ejection fraction. ESC Heart Fail 2018;5:372\u20138. https:\/\/doi.org\/10.1002\/ehf2.12235; PMID: 29345112. DOI: 10.1002\/ehf2.12235","DOI":"10.1002\/ehf2.12235"},{"key":"ref42","doi-asserted-by":"crossref","unstructured":"Chitsazan M, Parekh JK, Kosyakovsky LB, et al. Natriuretic peptide cut points for heart failure classification in individuals with and without obesity. Circ Heart Fail 2025;18:e013112. https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.125.013112; PMID: 40832688. DOI: 10.1161\/CIRCHEARTFAILURE.125.013112","DOI":"10.1161\/CIRCHEARTFAILURE.125.013112"},{"key":"ref43","doi-asserted-by":"crossref","unstructured":"Kozhuharov N, Martin J, Wussler D, et al. Clinical effect of obesity on N-terminal pro-B-type natriuretic peptide cut-off concentrations for the diagnosis of acute heart failure. Eur J Heart Fail 2022;24:1545\u201354. https:\/\/doi.org\/10.1002\/ejhf.2618; PMID: 35851710. DOI: 10.1002\/ejhf.2618","DOI":"10.1002\/ejhf.2618"},{"key":"ref44","doi-asserted-by":"crossref","unstructured":"Porter TR, Mulvagh SL, Abdelmoneim SS, et al. Clinical applications of ultrasonic enhancing agents in echocardiography: 2018 American Society of Echocardiography guidelines update. J Am Soc Echocardiogr 2018;31:241\u201374. https:\/\/doi.org\/10.1016\/j.echo.2017.11.013; PMID: 29502588. DOI: 10.1016\/j.echo.2017.11.013","DOI":"10.1016\/j.echo.2017.11.013"},{"key":"ref45","doi-asserted-by":"crossref","unstructured":"Kikuchi DS, Quinaglia T, Bukhari S, et al. Cardiac magnetic resonance imaging in heart failure with preserved ejection fraction. Circ Cardiovasc Imaging 2025;18:e018519. https:\/\/doi.org\/10.1161\/CIRCIMAGING.125.018519; PMID: 40843509. DOI: 10.1161\/CIRCIMAGING.125.018519","DOI":"10.1161\/CIRCIMAGING.125.018519"},{"key":"ref46","doi-asserted-by":"crossref","unstructured":"Basha M, Stavropoulou E, Nikolaidou A, et al. Diagnosing heart failure with preserved ejection fraction in obese patients. J Clin Med 2025;14:1980. https:\/\/doi.org\/10.3390\/jcm14061980; PMID: 40142788. DOI: 10.3390\/jcm14061980","DOI":"10.3390\/jcm14061980"},{"key":"ref47","doi-asserted-by":"crossref","unstructured":"Datta D, Normandin E, ZuWallack R. Cardiopulmonary exercise testing in the assessment of exertional dyspnea. Ann Thorac Med 2015;10:77\u201386. https:\/\/doi.org\/10.4103\/1817-1737.151438; PMID: 25829957. DOI: 10.4103\/1817-1737.151438","DOI":"10.4103\/1817-1737.151438"},{"key":"ref48","doi-asserted-by":"crossref","unstructured":"Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association joint committee on clinical practice guidelines. Circulation 2022;145:e895\u2013e1032. https:\/\/doi.org\/10.1161\/CIR.0000000000001063; PMID: 35363499. DOI: 10.1161\/CIR.0000000000001073","DOI":"10.1161\/CIR.0000000000001073"},{"key":"ref49","unstructured":"Kosiborod MN, Abildstr\u00f8m SZ, Borlaug BA, et al. Semaglutide in patients with heart failure with preserved ejection fraction and obesity. N Engl J Med 2023;389:1069\u201384. https:\/\/doi.org\/10.1056\/NEJMoa2306963; PMID: 37622681."},{"key":"ref50","doi-asserted-by":"crossref","unstructured":"Davies MJ, van der Meer P, Verma S, et al. Semaglutide in obesity-related heart failure with preserved ejection fraction and type 2 diabetes across baseline HbA1c levels (STEP-HFpEF DM): a prespecified analysis of heart failure and metabolic outcomes from a randomised, placebo-controlled trial. Lancet Diabetes Endocrinol 2025;13:196\u2013209. https:\/\/doi.org\/10.1016\/S2213-8587(24)00304-8; PMID: 39848268. DOI: 10.1016\/S2213-8587(24)00304-8","DOI":"10.1016\/S2213-8587(24)00304-8"},{"key":"ref51","doi-asserted-by":"crossref","unstructured":"Kosiborod MN, Deanfield J, Pratley R, et al. Semaglutide versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: a pooled analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomised trials. Lancet 2024;404:949\u201361. https:\/\/doi.org\/10.1016\/S0140-6736(24)01643-X; PMID: 39222642. DOI: 10.1016\/S0140-6736(24)01643-X","DOI":"10.1016\/S0140-6736(24)01643-X"},{"key":"ref52","doi-asserted-by":"crossref","unstructured":"Packer M, Zile MR, Kramer CM, et al. Tirzepatide for heart failure with preserved ejection fraction and obesity. N Engl J Med 2025;392:427\u201337. https:\/\/doi.org\/10.1056\/NEJMoa2410027; PMID: 39555826. DOI: 10.1056\/NEJMoa2410027","DOI":"10.1056\/NEJMoa2410027"},{"key":"ref53","doi-asserted-by":"crossref","unstructured":"Jorsal A, Kistorp C, Holmager P, et al. Effect of liraglutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE) \u2013 a multicentre, double-blind, randomised, placebo-controlled trial. Eur J Heart Fail 2017;19:69\u201377. https:\/\/doi.org\/10.1002\/ejhf.657; PMID: 27790809. DOI: 10.1002\/ejhf.657","DOI":"10.1002\/ejhf.657"},{"key":"ref54","doi-asserted-by":"crossref","unstructured":"Margulies KB, Hernandez AF, Redfield MM, et al. Effects of liraglutide on clinical stability among patients with advanced heart failure and reduced ejection fraction: a randomized clinical trial. JAMA 2016;316:500\u20138. https:\/\/doi.org\/10.1001\/jama.2016.10260; PMID: 27483064. DOI: 10.1001\/jama.2016.10260","DOI":"10.1001\/jama.2016.10260"},{"key":"ref55","unstructured":"Deanfield J, Verma S, Scirica BM, et al. Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial. Lancet 2024;404:773\u201386. https:\/\/doi.org\/10.1016\/S0140-6736(24)01498-3; PMID: 39181597."},{"key":"ref56","doi-asserted-by":"crossref","unstructured":"Pratley RE, Tuttle KR, Rossing P, et al. Effects of semaglutide on heart failure outcomes in diabetes and chronic kidney disease in the FLOW trial. J Am Coll Cardiol 2024;84:1615\u201328. https:\/\/doi.org\/10.1016\/j.jacc.2024.08.004; PMID: 39217553. DOI: 10.1016\/j.jacc.2024.08.004","DOI":"10.1016\/j.jacc.2024.08.004"},{"key":"ref57","doi-asserted-by":"crossref","unstructured":"Butt JH, Solomon SD, McMurray JJV. Incretin-based therapy for heart failure with reduced ejection fraction: why we need a trial. Eur Heart J 2026;47:64\u20138. https:\/\/doi.org\/10.1093\/eurheartj\/ehaf635; PMID: 40888808. DOI: 10.1093\/eurheartj\/ehaf635","DOI":"10.1093\/eurheartj\/ehaf635"},{"key":"ref58","doi-asserted-by":"crossref","unstructured":"Mehra MR, Canter CE, Hannan MM, et al. The 2016 International Society for Heart Lung Transplantation listing criteria for heart transplantation: a 10-year update. J Heart Lung Transplant 2016;35:1\u201323. https:\/\/doi.org\/10.1016\/j.healun.2015.10.023; PMID: 26776864. DOI: 10.1016\/j.healun.2015.10.023","DOI":"10.1016\/j.healun.2015.10.023"},{"key":"ref59","doi-asserted-by":"crossref","unstructured":"Diniz AMB, Veiga AL, Viana SW, et al. Impact of severe obesity on heart transplantation outcomes: a meta-analysis of survival and complications. JHLT Open 2026;11:100404. https:\/\/doi.org\/10.1016\/j.jhlto.2025.100404; PMID: 41312402. DOI: 10.1016\/j.jhlto.2025.100404","DOI":"10.1016\/j.jhlto.2025.100404"},{"key":"ref60","doi-asserted-by":"crossref","unstructured":"Goubar T, Kim S, Cistulli D, et al. Sleeve gastrectomy as a bridge to cardiac recovery \u2013 a retrospective comparative cohort study. JHLT Open 2025;8:100224. https:\/\/doi.org\/10.1016\/j.jhlto.2025.100224; PMID: 40144731. DOI: 10.1016\/j.jhlto.2025.100224","DOI":"10.1016\/j.jhlto.2025.100224"},{"key":"ref61","doi-asserted-by":"crossref","unstructured":"Perkovic V, Tuttle KR, Rossing P, et al. Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes. N Engl J Med 2024;391:109\u201321. https:\/\/doi.org\/10.1056\/NEJMoa2403347; PMID: 38785209. DOI: 10.1056\/NEJMoa2403347","DOI":"10.1056\/NEJMoa2403347"},{"key":"ref62","doi-asserted-by":"crossref","unstructured":"Loomba R, Hartman ML, Lawitz EJ, et al. Tirzepatide for metabolic dysfunction\u2013associated steatohepatitis with liver fibrosis. N Engl J Med 2024;391:299\u2013310. https:\/\/doi.org\/10.1056\/NEJMoa2401943; PMID: 38856224. DOI: 10.1056\/NEJMoa2401943","DOI":"10.1056\/NEJMoa2401943"},{"key":"ref63","doi-asserted-by":"crossref","unstructured":"Sanyal AJ, Newsome PN, Kliers I, et al. Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis. N Engl J Med 2025;392:2089\u201399. https:\/\/doi.org\/10.1056\/NEJMoa2413258; PMID: 40305708. DOI: 10.1056\/NEJMoa2413258","DOI":"10.1056\/NEJMoa2413258"},{"key":"ref64","doi-asserted-by":"crossref","unstructured":"Malhotra A, Grunstein RR, Fietze I, et al. Tirzepatide for the treatment of obstructive sleep apnea and obesity. N Engl J Med 2024;391:1193\u2013205. https:\/\/doi.org\/10.1056\/NEJMoa2404881; PMID: 38912654. DOI: 10.1056\/NEJMoa2404881","DOI":"10.1056\/NEJMoa2404881"},{"key":"ref65","doi-asserted-by":"crossref","unstructured":"Shchendrygina A, Rakisheva A, Giverts I, et al. Effects of glucagon-like peptide-1 receptor agonists on cardiac function, exercise capacity and quality of life. Card Fail Rev 2024;10:e10. https:\/\/doi.org\/10.15420\/cfr.2024.05; PMID: 39309521. DOI: 10.15420\/cfr.2024.05","DOI":"10.15420\/cfr.2024.05"},{"key":"ref66","doi-asserted-by":"crossref","unstructured":"Bonfioli GB, Pagnesi M, Tomasoni D, et al. Understanding the role of glucagon-like peptide-1 receptor agonists in the treatment of heart failure. Card Fail Rev 2025;11:e19. https:\/\/doi.org\/10.15420\/cfr.2025.10; PMID: 40901556. DOI: 10.15420\/cfr.2025.10","DOI":"10.15420\/cfr.2025.10"},{"key":"ref67","doi-asserted-by":"crossref","unstructured":"Neeland IJ, Linge J, Birkenfeld AL. Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategies. Diabetes Obes Metab 2024;26(Suppl 4):16\u201327. https:\/\/doi.org\/10.1111\/dom.15728; PMID: 38937282. DOI: 10.1111\/dom.15728","DOI":"10.1111\/dom.15728"},{"key":"ref68","doi-asserted-by":"crossref","unstructured":"Linge J, Birkenfeld AL, Neeland IJ. Muscle mass and glucagon-like peptide-1 receptor agonists: adaptive or maladaptive response to weight loss? Circulation 2024;150:1288\u201398. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.124.067676; PMID: 39401279. DOI: 10.1161\/CIRCULATIONAHA.124.067676","DOI":"10.1161\/CIRCULATIONAHA.124.067676"},{"key":"ref69","doi-asserted-by":"crossref","unstructured":"Shahrvini T, Asgar J, Bhatt R, et al. Abstract 4343038: Effects of cardiac rehabilitation on body composition changes in patients receiving GLP-1 receptor agonists. Circulation 2025;152(Suppl 3):A4343038. https:\/\/doi.org\/10.1161\/circ.152.suppl_3.4343038. DOI: 10.1161\/circ.152.suppl_3.4343038","DOI":"10.1161\/circ.152.suppl_3.4343038"},{"key":"ref70","doi-asserted-by":"crossref","unstructured":"Jensen SBK, S\u00f8rensen V, Sandsdal RM, et al. Bone health after exercise alone, GLP-1 receptor agonist treatment, or combination treatment: a secondary analysis of a randomized clinical trial. JAMA Netw Open 2024;7:e2416775. https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.16775; PMID: 38916894. DOI: 10.1001\/jamanetworkopen.2024.16775","DOI":"10.1001\/jamanetworkopen.2024.16775"},{"key":"ref71","doi-asserted-by":"crossref","unstructured":"Nauck MA, Tuttle KR, Tsch\u00f6p MH, Bl\u00fcher M. Glucagon-like receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits. Lancet 2026:407;892\u2013908. https:\/\/doi.org\/10.1016\/s0140-6736(25)02105-1; PMID: 41547366. DOI: 10.1016\/S0140-6736(25)02105-1","DOI":"10.1016\/S0140-6736(25)02105-1"},{"key":"ref72","doi-asserted-by":"crossref","unstructured":"West S, Scragg J, Aveyard P, et al. Weight regain after cessation of medication for weight management: systematic review and meta-analysis. BMJ 2026;392:e085304. https:\/\/doi.org\/10.1136\/bmj-2025-085304; PMID: 41500720. DOI: 10.1136\/bmj-2025-085304","DOI":"10.1136\/bmj-2025-085304"}],"container-title":["Cardiac Failure Review"],"original-title":[],"link":[{"URL":"https:\/\/www.cfrjournal.com\/articleindex\/cfr.2026.05","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T10:54:39Z","timestamp":1788951279000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cfrjournal.com\/articleindex\/cfr.2026.05"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,8]]},"references-count":73,"URL":"https:\/\/doi.org\/10.15420\/cfr.2026.05","relation":{},"ISSN":["2057-7540","2057-7559"],"issn-type":[{"value":"2057-7540","type":"print"},{"value":"2057-7559","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,8]]},"article-number":"e26"}}